Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ticagrelor in Chinese Patients With Acute Coronary Syndrome (DaYu)
NCT01870921Phase 4Completed
- Sponsor
- AstraZeneca
- Start
- Jun 2013
- Primary completion
- Sep 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ticagrelor in acute coronary syndrome (ACS), sponsored by AstraZeneca. Primary endpoints: Bleeding Events at 12 months and Serious Adverse Events Other Than Bleeding at 12 months. Started Jun 2013; status: completed.
02
Drugs
ticagrelor
03
Conditions
acute coronary syndrome (ACS)
Beyond the preview
Go deeper on NCT01870921.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01870921.